<p>美国制药巨头礼来（Eli Lilly，LLY）又向其位于印第安纳州的制造设施投资了 45 亿美元，这是其国内制造扩张的关键支柱。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>自 2020 年以来，该公司在这些设施上的投资已超过 210 亿美元。公司表示，这笔资金将用于支持先进商业基因疗法的开发，并生产其每日一次的肥胖药物 Foundayo。</p>
<h2><strong>肥胖药物成为减肥竞赛的新前沿</strong></h2>
<p>该公告发布的几天前，这家位于印第安纳州的公司超出了 2026 年第一季度的利润和销售预期，其受欢迎的 GLP-1 药物 Zepbound（用于肥胖）和 Mounjaro（用于 2 型糖尿病）的需求依然强劲。GLP-1 或胰高血糖素样肽-1 是一种管理血糖和食欲的激素，在减肥药物中发挥着关键作用。</p>
<p>礼来也强调了 Foundayo 早期强劲的市场反响，该药物在上个月初获得美国监管机构的批准，并在首周内被开处方近 1400 次。然而，丹麦的主要竞争对手诺和诺德（Novo Nordisk，NVO）——在首个口服减肥药物方面领先于礼来——也在其 Wegovy 药物上获得了强劲的市场反响。</p>
<p>这帮助这家丹麦制药巨头报告了强于预期的第一季度收益，并使其有信心下调全年调整后销售和营业利润下降的预测。</p>
<h2><strong>礼来推动国内制造扩张</strong></h2>
<p>与此同时，除了 Foundayo，礼来还表示，这笔资金将用于生产 retatrutide，这是一种处于后期开发阶段的药物，旨在治疗肥胖和心代谢疾病。后者指的是与心脏和代谢相关的疾病——即能量、糖和脂肪分解的问题。</p>
<p>这项投资计划用于礼来在印第安纳州黎巴嫩的三个地点中的两个。前两个是 Lilly Lebanon API，用于未来活性药物成分的生产，以及 Lilly Lebanon Advanced Therapies，用于基因医学的开发。</p>
<p>最后一个是 Lilly Medicine Foundry，用于临床试验药物的生产。礼来表示，自 2020 年以来，已承诺在美国制造方面投资超过 500 亿美元。</p>
<h2><strong>礼来仍然是一个值得购买的好股票吗？</strong></h2>
<p>在华尔街，礼来的股票继续享有分析师的强烈买入共识评级。这是基于过去三个月 22 位分析师发布的 19 个买入、2 个持有和 1 个卖出评级。</p>
<p>该评级的平均目标价为 1262.85 美元，意味着未来几个月大约有 28% 的上涨空间。</p>

礼来

2 倍做多 LLY ETF - Defiance

2 倍做多 NVO ETF - Defiance

<p>礼来（LLY）在其印第安纳州的制造设施中额外投资了 45 亿美元，使其自 2020 年以来的总投资超过 210 亿美元。这笔资金支持先进基因疗法的开发以及其新型减肥药 Foundayo，该药物已初步显示出强劲的需求。此次投资还旨在增强对抗肥胖和心代谢疾病的药物 retatrutide 的生产能力。分析师对礼来的股票维持强烈买入的共识，目标价暗示有 28% 的上涨空间</p>

<p>U.S. pharma giant Eli Lilly (LLY) has pumped another $4.5 billion investment into its manufacturing facilities in Indiana, a key anchor of its domestic manufacturing buildout.</p>
<div class="lb-trans"><p>美国制药巨头礼来（Eli Lilly，LLY）又向其位于印第安纳州的制造设施投资了 45 亿美元，这是其国内制造扩张的关键支柱。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>The figure has raised its investment in these facilities since 2020 to more than $21 billion. The company said the capital is to support the development of advanced commercial gene therapies and to produce Foundayo, its once-daily obesity pill.</p>
<div class="lb-trans"><p>自 2020 年以来，该公司在这些设施上的投资已超过 210 亿美元。公司表示，这笔资金将用于支持先进商业基因疗法的开发，并生产其每日一次的肥胖药物 Foundayo。</p>
</div><h2><strong>Obesity Pill Emerges as New Frontier in Weight-Loss Race</strong></h2>
<div class="lb-trans"><h2><strong>肥胖药物成为减肥竞赛的新前沿</strong></h2>
</div><p>The announcement comes days after the Indiana-based company smashed estimates for both its first-quarter 2026 profit and sales, with demand for its popular GLP-1 drugs, Zepbound for obesity and Mounjaro for type II diabetes, remaining robust. GLP-1, or glucagon-like peptide-1, is a hormone that manages blood sugar and appetite and plays a key role in weight-loss medications.</p>
<div class="lb-trans"><p>该公告发布的几天前，这家位于印第安纳州的公司超出了 2026 年第一季度的利润和销售预期，其受欢迎的 GLP-1 药物 Zepbound（用于肥胖）和 Mounjaro（用于 2 型糖尿病）的需求依然强劲。GLP-1 或胰高血糖素样肽-1 是一种管理血糖和食欲的激素，在减肥药物中发挥着关键作用。</p>
</div><p>Eli Lilly also stressed early signs of robust reception of Foundayo, which secured approval from U.S. regulatory authorities early last month and was prescribed nearly 1,400 times in its first week. However, key rival Denmark-based Novo Nordisk (NVO) — which beat Eli Lilly to the first oral weight-loss medication — is also seeing strong reception of its Wegovy pill.</p>
<div class="lb-trans"><p>礼来也强调了 Foundayo 早期强劲的市场反响，该药物在上个月初获得美国监管机构的批准，并在首周内被开处方近 1400 次。然而，丹麦的主要竞争对手诺和诺德（Novo Nordisk，NVO）——在首个口服减肥药物方面领先于礼来——也在其 Wegovy 药物上获得了强劲的市场反响。</p>
</div><p>This helped the Danish pharma heavyweight to report stronger-than-expected first-quarter earnings and gave it the confidence to trim its adjusted sales and operating profit decline projection for the full fiscal year.</p>
<div class="lb-trans"><p>这帮助这家丹麦制药巨头报告了强于预期的第一季度收益，并使其有信心下调全年调整后销售和营业利润下降的预测。</p>
</div><h2><strong>Eli Lilly Boosts Domestic Manufacturing Buildout</strong></h2>
<div class="lb-trans"><h2><strong>礼来推动国内制造扩张</strong></h2>
</div><p>Meanwhile, apart from Foundayo, Eli Lilly also said the capital injection will go to the production of retatrutide, a drug in late-stage development that is targeted at treating both obesity and cardiometabolic diseases. The latter refers to conditions related to the heart and metabolism — or energy, sugar, and fat breakdown — problems.</p>
<div class="lb-trans"><p>与此同时，除了 Foundayo，礼来还表示，这笔资金将用于生产 retatrutide，这是一种处于后期开发阶段的药物，旨在治疗肥胖和心代谢疾病。后者指的是与心脏和代谢相关的疾病——即能量、糖和脂肪分解的问题。</p>
</div><p>The investment is planned for two of Eli Lilly's three sites in Lebanon, Indiana. The first two are the Lilly Lebanon API for future production of active pharmaceutical ingredients and the Lilly Lebanon Advanced Therapies for genetic medicine development.</p>
<div class="lb-trans"><p>这项投资计划用于礼来在印第安纳州黎巴嫩的三个地点中的两个。前两个是 Lilly Lebanon API，用于未来活性药物成分的生产，以及 Lilly Lebanon Advanced Therapies，用于基因医学的开发。</p>
</div><p>The last one is the Lilly Medicine Foundry for the production of medicines for clinical trials. Eli Lilly said it has committed overall more than $50 billion in investments since 2020 to boost its U.S. manufacturing.</p>
<div class="lb-trans"><p>最后一个是 Lilly Medicine Foundry，用于临床试验药物的生产。礼来表示，自 2020 年以来，已承诺在美国制造方面投资超过 500 亿美元。</p>
</div><h2><strong>Is Eli Lilly Still a Good Stock to Buy?</strong></h2>
<div class="lb-trans"><h2><strong>礼来仍然是一个值得购买的好股票吗？</strong></h2>
</div><p>On Wall Street, Eli Lilly's shares continue to enjoy a Strong Buy consensus rating from analysts. This is based on 19 Buys, two Holds, and one Sell issued by 22 analysts over the past three months.</p>
<div class="lb-trans"><p>在华尔街，礼来的股票继续享有分析师的强烈买入共识评级。这是基于过去三个月 22 位分析师发布的 19 个买入、2 个持有和 1 个卖出评级。</p>
</div><p>The rating comes with an average LLY price target of $1,262.85 that implies roughly 28% upside in the months ahead.</p>
<div class="lb-trans"><p>该评级的平均目标价为 1262.85 美元，意味着未来几个月大约有 28% 的上涨空间。</p>
</div>

礼来（LLY）在与诺和诺德的肥胖药物竞争中将赌注提高至 210 亿美元